These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2693187

  • 1. [The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
    Meier W, Eiermann W, Stieber P, Fateh-Moghadam A, Hepp H.
    Geburtshilfe Frauenheilkd; 1989 Dec; 49(12):1050-5. PubMed ID: 2693187
    [Abstract] [Full Text] [Related]

  • 2. Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy.
    Meier W, Eiermann W, Stieber P, Fateh-Moghadam A, Schneider A, Hepp H.
    Gynecol Oncol; 1990 Jul; 38(1):6-11. PubMed ID: 2191907
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of squamous cell carcinoma (SCC) antigen in primary advanced and recurrent cervical carcinoma.
    Meier W, Stieber P, Hasholzner U, Baumgartner L, Fateh-Moghadam A.
    Anticancer Res; 1997 Jul; 17(4B):2959-62. PubMed ID: 9329575
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G, Fei F, Mangioni C.
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study.
    Eddy GL, Manetta A, Alvarez RD, Williams L, Creasman WT.
    Gynecol Oncol; 1995 Jun; 57(3):412-6. PubMed ID: 7774847
    [Abstract] [Full Text] [Related]

  • 6. [The course of squamous cell cancer antigen in chemotherapy as a prognostic criterion in cervix cancer].
    Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H.
    Gynakol Rundsch; 1989 Jun; 29 Suppl 2():411-2. PubMed ID: 2613066
    [No Abstract] [Full Text] [Related]

  • 7. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
    Sugiyama T, Nishida T, Hasuo Y, Fujiyoshi K, Yakushiji M.
    Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
    [Abstract] [Full Text] [Related]

  • 8. [SCC (squamous cell carcinoma) antigen as a tumor marker in cervix cancers].
    Geyer H, Schwörer D, Pfleiderer A.
    Geburtshilfe Frauenheilkd; 1989 Mar; 49(3):266-71. PubMed ID: 2721888
    [Abstract] [Full Text] [Related]

  • 9. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
    Duk JM, Aalders JG, Fleuren GJ, Krans M, De Bruijn HW.
    Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
    [Abstract] [Full Text] [Related]

  • 10. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
    Juang CM, Wang PH, Yen MS, Lai CR, Ng HT, Yuan CC.
    Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
    [Abstract] [Full Text] [Related]

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 12. [Combination chemotherapy with 254-S, ifosfamide and peplomycin for advanced or recurrent cervical cancer].
    Hirabayashi K, Okada E, Nakazuma Y, Akamatsu Y, Sezaki H, Ohta M, Nakanishi Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Mar; 44(3):341-8. PubMed ID: 1376759
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bleomycin, cisplatinum and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix.
    Singhal RM, Jindel R, Gupta AK.
    Indian J Cancer; 1993 Dec; 30(4):158-63. PubMed ID: 7515843
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
    Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ.
    Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
    [Abstract] [Full Text] [Related]

  • 18. [Determination of the SCC antigen in the serum of patients with cervical cancer].
    Crombach G, Würz H, Bolte A.
    Geburtshilfe Frauenheilkd; 1987 Jul; 47(7):439-45. PubMed ID: 3623046
    [Abstract] [Full Text] [Related]

  • 19. [Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide].
    Chauvergne J, Héron JF, Mayer F, Charrot-Chinet P, Toulouse C.
    Bull Cancer; 1993 Jan; 80(1):70-9. PubMed ID: 7515729
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix.
    Bae SN, Namkoong SE, Jung JK, Kim CJ, Park JS, Kim JW, Lee JM, Kim SJ.
    Gynecol Oncol; 1997 Mar; 64(3):418-24. PubMed ID: 9062143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.